phase III failure

Showing 8 posts of 8 posts found.


Tonix tanks after Phase III failure

September 7, 2016
Research and Development PTSD, fibromylagia, phase III failure, tonix, tonix pharmaceuticals

New York-based Tonix Pharmaceuticals has suffered an almost 60% fall in their share price, after the announcement that its fibromyalgia …


Vectura asthma treatment fails at Phase III

August 30, 2016
Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura

Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …


LMTX fails Phase III trial, monotherapy benefits seen

July 28, 2016
Research and Development Alzheimer's, LMTX, TauRX, phase III, phase III failure

TauRX Therapeutics has reported Phase III clinical trial results for its novel tau aggregation inhibitor LMTX. The results indicated that …


Lilly pulls plug on basal insulin Peglispro

December 8, 2015
Manufacturing and Production R&D, basal insulin peglispro, diabetes, lilly, peglispro, phase III failure

Lilly has decided to pull out of filing its diabetes drug basal insulin peglispro, after failing to convince regulators and …


Genmab pulls plug on Phase III Arzerra trial

November 24, 2015
Manufacturing and Production, Research and Development Arzerra, Genmab, non-Hodgkin's lymphoma, non-Hodgkin’s lymphoma, ofatumumab, phase III, phase III failure

Genmab has stopped a Phase III study of its CD20-directed monoclonal antibody Arzerra, after it was shown to be unlikely …


Otsuka, GW announce Sativex fails in Phase III cancer pain trials

October 28, 2015
Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure

Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …


Lilly shares fall as company abandons evacetrapib development

October 13, 2015
Manufacturing and Production evacetrapib, high cholesterol, lilly, phase III, phase III failure

Eli Lilly shares fell by nearly 8% this week as the company announced it will abandon developmenty of the investigational …

Roche image

Roche abandons Phase III cholesterol drug

May 8, 2012
Medical Communications, Research and Development, Sales and Marketing CETP inhibitor, Roche, cardiovascular, dalcetrapib, phase III failure

Roche has abandoned its Phase III cholesterol treatment dalcetrapib after disappointing results.The manufacturer is ceasing work on the drug, once …

Latest content